|
|
|
JACI Highlights - July 2006
Jarjour et al - Control of airway inflammation maintained at a lower steroid dose with fluticasone propionate/salmeterol 100/50mcg
In the July 2006 issue of the Journal of Allergy and Clinical Immunology, Jarjour et al compare the use of medium-dose inhaled corticosteroid in asthma management with the use of a lower-dose inhaled corticosteroid administered with a long-acting 2-agonist. Although inhaled corticosteroids are the mainstay in asthma management, their long-term use can be associated with side effects affecting bone density, the skin, and the eyes, particularly when they are used at high doses for prolonged periods of time. Therefore, a lower dose of inhaled corticosteroids is desirable. The authors found that control of asthma and airway inflammation can be maintained over a 24-week treatment period when patients requiring a medium dose of inhaled corticosteroid are switched to a lower dose inhaled corticosteroid in combination with a long-acting 2-agonist.
<back>
|
